◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 6821

Asymchem Laboratories (Tianjin) Co., Ltd. (6821) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Asymchem Laboratories (Tianjin) Co., Ltd. (6821) operates in the Biotechnology industry and is headquartered in Tianjin, China with about 10,617 employees. Its market capitalization is roughly CNY 43 billion. In the fiscal year ended 2025-12-31, 6821 reported CNY 6.7B in revenue and CNY 1.1B in net income.

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally.

Interactive charts & full statements →

6821 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 6.7B	CNY 5.8B	CNY 7.8B	CNY 10.3B
Gross Profit	CNY 2.8B	CNY 2.5B	CNY 4.0B	CNY 4.9B
Operating Income (EBIT)	CNY 1.3B	CNY 702M	CNY 2.3B	CNY 3.2B
Net Income	CNY 1.1B	CNY 949M	CNY 2.3B	CNY 3.3B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6821 Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CNY 1.8B	CNY 2.0B	—	CNY 1.6B	CNY 1.5B	CNY 1.7B
Gross Profit	CNY 775M	CNY 836M	—	CNY 731M	CNY 656M	CNY 654M
Operating Income (EBIT)	CNY 404M	CNY 438M	—	CNY 354M	CNY 295M	CNY 128M
Net Income	CNY 304M	CNY 332M	—	CNY 291M	CNY 327M	CNY 239M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6821 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 395M)	(CNY 642M)	(CNY 664M)	(CNY 219M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6821 Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Dividends Paid	—	CNY 0M	—	—	(CNY 2M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6821 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 20.3B	CNY 19.3B	CNY 19.8B	CNY 18.2B	—
Total Liabilities	CNY 2.6B	CNY 2.4B	CNY 2.3B	CNY 2.5B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6821 viewer.

Other Companies in Biotechnology

1548 · Genscript Biotech Corporation — $54 billion
9995 · RemeGen Co., Ltd. — $51 billion
3759 · Pharmaron Beijing Co., Ltd. — $50 billion
1530 · 3SBio Inc. — $44 billion
2696 · Shanghai Henlius Biotech, Inc. — $37 billion
BIIB · Biogen — $31 billion
2315 · Biocytogen Pharmaceuticals (Beijing) Co., Ltd. — $30 billion
MRNA · Moderna — $25 billion

← 6820 All “0-9” companies 6822 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.